Lentiviral vector transduction of NOD/SCID repopulating cells results in multiple vector integrations per transduced cell: risk of insertional mutagenesis.

Efficient vector transduction of hematopoietic stem cells is a requirement for successful gene therapy of hematologic disorders. We asked whether human umbilical cord blood CD34(+)CD38(lo) nonobese diabetic/severe combined immunodeficiency (NOD/SCID) repopulating cells (SRCs) could be efficiently transduced using lentiviral vectors, with a particular focus on the average number of vector copies integrating into these primitive progenitor cells. Mouse bone marrow was analyzed by fluorescence-activated cell-sorter scanner and by semiquantitative polymerase chain reaction (PCR) to determine the transduction efficiency into SRCs. Lentiviral vector transduction resulted in an average of 22% (range, 3%-90%) of the human cells expressing green fluorescent protein (GFP), however, multiple vector copies were present in human hematopoietic cells, with an average of 5.6 +/- 3.3 (n = 12) copies per transduced cell. To confirm the ability of lentiviral vectors to integrate multiple vector copies into SRCs, linear amplification mediated (LAM)-PCR was used to analyze the integration site profile of a selected mouse showing low-level engraftment and virtually all human cells expressing GFP. Individually picked granulocyte macrophage colony-forming unit colonies derived from the bone marrow of this mouse were analyzed and shown to have the same 5 vector integrants within each colony. Interestingly, one integration site of the 5 that were sequenced in this mouse was located in a known tumor-suppressor gene, BRCA1. Therefore, these findings demonstrate the ability of lentiviral vectors to transduce multiple copies into a subset of NOD/SCID repopulating cells. While this is efficient in terms of transduction and transgene expression, it may increase the risk of insertional mutagenesis.

[1]  C. von Kalle,et al.  Polyclonal long-term repopulating stem cell clones in a primate model. , 2002, Blood.

[2]  Paul Shinn,et al.  HIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots , 2002, Cell.

[3]  C. von Kalle,et al.  Murine Leukemia Induced by Retroviral Gene Marking , 2002, Science.

[4]  David Baltimore,et al.  Germline Transmission and Tissue-Specific Expression of Transgenes Delivered by Lentiviral Vectors , 2002, Science.

[5]  C. von Kalle,et al.  Detection and direct genomic sequencing of multiple rare unknown flanking DNA in highly complex samples. , 2001, Human gene therapy.

[6]  P. Charneau,et al.  Enhanced transgene expression in cord blood CD34(+)-derived hematopoietic cells, including developing T cells and NOD/SCID mouse repopulating cells, following transduction with modified trip lentiviral vectors. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  S. Karlsson,et al.  Clinical Gene Therapy in Hematology: Past and Future , 2001, International journal of hematology.

[8]  M. Grez,et al.  MDR1 gene expression in NOD/SCID repopulating cells after retroviral gene transfer under clinically relevant conditions. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  S. Karlsson,et al.  Lentiviral gene transfer into primary and secondary NOD/SCID repopulating cells. , 2000, Blood.

[10]  S. Karlsson,et al.  Lentivirus Vector Gene Expression during ES Cell-Derived Hematopoietic Development In Vitro , 2000, Journal of Virology.

[11]  D. Trono,et al.  High-level transgene expression in human hematopoietic progenitors and differentiated blood lineages after transduction with improved lentiviral vectors. , 2000, Blood.

[12]  D. Trono,et al.  Reversible immortalization of human primary cells by lentivector-mediated transfer of specific genes. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[13]  D. Trono,et al.  A stable system for the high-titer production of multiply attenuated lentiviral vectors. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[14]  D. Haas,et al.  Critical factors influencing stable transduction of human CD34(+) cells with HIV-1-derived lentiviral vectors. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[15]  J. Dick,et al.  Transduction of human CD34+ CD38- bone marrow and cord blood-derived SCID-repopulating cells with third-generation lentiviral vectors. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[16]  B. Koller,et al.  Brca1 controls homology-directed DNA repair. , 1999, Molecular cell.

[17]  T. Hope,et al.  Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element Enhances Expression of Transgenes Delivered by Retroviral Vectors , 1999, Journal of Virology.

[18]  L. Naldini,et al.  Stable transduction of quiescent CD34(+)CD38(-) human hematopoietic cells by HIV-1-based lentiviral vectors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[19]  B. Torbett,et al.  Transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. , 1999, Science.

[20]  I. Kato,et al.  Adhesion to fibronectin maintains regenerative capacity during ex vivo culture and transduction of human hematopoietic stem and progenitor cells. , 1998, Blood.

[21]  J. Cancelas,et al.  Highly efficient transduction of the green fluorescent protein gene in human umbilical cord blood stem cells capable of cobblestone formation in long-term cultures and multilineage engraftment of immunodeficient mice. , 1998, Blood.

[22]  D. Trono,et al.  Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery , 1998, Journal of Virology.

[23]  I. Weissman,et al.  HIV, but not murine leukemia virus, vectors mediate high efficiency gene transfer into freshly isolated G0/G1 human hematopoietic stem cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[24]  J. Nolta,et al.  Clonal diversity of primitive human hematopoietic progenitors following retroviral marking and long-term engraftment in immune-deficient mice. , 1997, Experimental hematology.

[25]  T. Jacks,et al.  Double indemnity: p53, BRCA and cancer , 1997, Nature Medicine.

[26]  T. Jacks,et al.  Double indemnity: p53, BRCA and cancer. p53 mutation partially rescues developmental arrest in Brca1 and Brca2 null mice, suggesting a role for familial breast cancer genes in DNA damage repair. , 1997, Nature medicine.

[27]  F. Gage,et al.  In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector , 1996, Science.

[28]  D. Easton,et al.  Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. , 1993, American journal of human genetics.

[29]  Thorsten Wagener,et al.  Distinct classes of factor-independent mutants can be isolated after retroviral mutagenesis of a human myeloid stem cell line. , 1993, Growth factors.

[30]  W. Ostertag,et al.  Embryonic stem cell virus, a recombinant murine retrovirus with expression in embryonic stem cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.